The phase 3 CABINET trial evaluated cabozantinib versus placebo in patients with previously treated neuroendocrine tumors. Data from this...

SubjectWell bolsters its global patient recruitment capabilities by acquiring Trials24. The merger combines SubjectWell’s accuracy, diverse patient pool, and...

DeepCure, a company employing AI for drug discovery, will present preclinical data on their BRD4 Inhibitor, DC-9476, at the...

Ferrer, a B Corp-certified pharmaceutical company, has initiated a Phase II clinical trial, PROSPER, to assess the safety and...

CD137 (4-1BB) is a promising target for cancer immunotherapy. Its ability to stimulate T cells and enhance tumor cell...

Nature’s Toolbox (NTx) has launched NTx Services, providing high-integrity, complex mRNA production using its innovative NTxscribe® RNA manufacturing system....

Tivic Health has received approval for the next phase of clinical research on its non-invasive cervical vagus nerve stimulation...

Azitra, a biopharmaceutical company specializing in precision dermatology, has announced the FDA’s Fast Track Designation for ATR-04, a novel...

AstraZeneca’s FASENRA (benralizumab) has received FDA approval for treating adults with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune...

According to new data, a Phase 3 extension study of Zeposia for multiple sclerosis (MS) found a sustained decrease...